Your post makes me ponder: Is an inkblot ever just an inkblot, or is it always more? I guess the other side can be asked: Is an inkblot always just an inkblot?
Pardon me, time to take my meds :-)
Seriously, follow the nwbo dcvax breadcrumbs:
+ compassionate use continuing
+ Sawston build, certification, Flaskworks
+ combo trials with dcvax as control
+ blinded results imply SOC potential
+ acceptance of OS as primary endpoint
+ data lock over 7 months ago no fail
+ LL investigation of Dcvax combo apoptosis
+ MULTIPLE DCVAX TREATED GBM PATIENTS LIVING MORE THAN 8, 10, 12 years?
+ 80+ reputable trial sites and neurosurgeons participated in phase3 and no negative leaks from any of them as far as I know
All this doesn’t guarantee trial and investment success but I’d rather strike out swinging at this pitch than thinking shoulda coulda for a long time (fomo and yolo), but as I’ve stated before I have struck out swinging for the fences before and never for the amount of hard cash at stake in nwbo!
News 
Market Data 
Discover 
